Investors in the biotech sector were glued last week to the highly awaited 54th …
With such steady profitable growth, you would expect a stock chart that goes straight up. Nope. Regeneron has traded as high as $577 per share in early 2015, when drugs were in fashion, and as low as $300 per share in May, when they …
Regeneron reported exceptionally strong earnings growth in the first quarter. Dupixent prescriptions strong. Coverage for expensive therapy a headwind for revenue growth. If the stock market needed a poster child for irrational behavior, then …
Shares of Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) created a high-water mark around three and a half years ago that's still 51% above recent prices. The drugs it outlicensed to its big pharma partner, Sanofi (NYSE: SNY), …
Regeneron Pharm (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $294.18 to a high of $304.31. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $297.47 on volume of 292,000 …
Shares of Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) created a high-water mark around three and a half years ago that's still 51% above recent prices. The drugs it outlicensed to its big pharma partner, Sanofi (NYSE: SNY), …
Shares of Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) created a high-water mark around three and a half years ago that's still 51% above recent prices. The drugs it outlicensed to its big pharma partner, Sanofi (NYSE: SNY), …
Shares of Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) created a high-water mark around three and a half years ago that's still 51% above recent prices. The drugs it outlicensed to its big pharma partner, Sanofi (NYSE: SNY), …
Yahoo!1mon